Status:
UNKNOWN
The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
Lead Sponsor:
Assiut University
Conditions:
Warts
Eligibility:
All Genders
15-40 years
Phase:
PHASE4
Brief Summary
* Warts are common viral infections on the skin and are prevalent worldwide. Warts are caused by the human Papilloma virus (HPV), which has more than 100 strains; some of them are known to be premalig...
Detailed Description
* Selection of the most appropriate means of treatment is usually difficult because of the availability of various therapeutic lines and also due to the variability in the immune status of the patient...
Eligibility Criteria
Inclusion
- Patients with positive tuberculin test or with past history of PPD vaccination will include.
- Patient with normal CBC , liver function and renal function
Exclusion
- Patients with immunosuppression, pregnancy, or lactation, with negative tuberculin test or with past history of tuberculosis, peripheral vascular disease, any abnormality in liver or renal function and those who received any wart treatment 1 month before the start of the study will exclude.
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03477448
Start Date
April 1 2018
End Date
April 1 2020
Last Update
March 26 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.